DM&M Consulting and Solutions

Research and science

Where this helps

There are more compounds than the lab can screen. The team needs a reason to test a few of them first.

A long list of equally interesting compounds spends the months a program needs for learning. We apply AI and data-driven methods to prioritize candidates and predicted properties. The result is a shorter list with reasons attached. It prepares the experiment. It does not replace laboratory validation, and it is not a discovered drug.

This work supports research decisions. It does not replace laboratory validation.

You are ready to start if

  • A discovery decision is actually stuck
  • You accept that a model prepares the experiment and does not replace it
  • You want the thin spots named, not hidden

What waiting looks like

Unfocused screening uses the months the program needed for learning, and the question does not get sharper.

Not the right fit. If you need a discovered drug, or a guarantee a candidate will work in the lab, we are the wrong call.

What you leave with

  • A shorter list of compounds worth a closer look
  • Property predictions that help you decide what moves up
  • An honest line between what computation can prioritize and what the lab must still test

Who books this

Discovery teams and biotech groups choosing what to test next.